# A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

> **NCT02873962** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 72 (actual)

## Conditions studied

- Peritoneal Cancer
- Ovarian Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Nivolumab
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT02873962
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-10
- **Primary completion:** 2025-02
- **Final completion:** 2027-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873962, "A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT02873962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*